[New European approvals: Tisagenlecleucel and Axicabtagene ciloleucel CAR-T cells - Follicular lymphoma after at least two and three prior lines of therapy]

Bull Cancer. 2022 Nov;109(11):1106-1108. doi: 10.1016/j.bulcan.2022.07.003. Epub 2022 Sep 7.

[Article in French]

Authors

Stéphanie Cordeil¹, Emmanuel Bachy²

Affiliations

¹ Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, service d'hématologie, 69495 Pierre Bénite cedex, France.
² Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, service d'hématologie, 69495 Pierre Bénite cedex, France; Université Claude Bernard Lyon-1, 69100 Villeurbanne, France. Electronic address: emmanuel.bachy@chu-lyon.fr.

PMID: 36088178
DOI: 10.1016/j.bulcan.2022.07.003

No abstract available

Keywords: CAR-T cells; Cellules CAR-T; Follicular lymphoma; Lymphome folliculaire; Rechute; Refractory; Relapse; Réfractaire.

Publication types

Letter

MeSH terms

Antigens, CD19 / therapeutic use
Humans
Immunotherapy, Adoptive
Lymphoma, Follicular* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / therapy
T-Lymphocytes

Substances

tisagenlecleucel
axicabtagene ciloleucel
Antigens, CD19